Safety and efficacy of long-term enzyme replacement therapy with velaglucerase alfa in patients with type 1 Gaucher disease transitioned from imiglucerase
Deborah Elstein(Shaare Zedek Medical Center), Ari Zimran(Hebrew University of Jerusalem), Laurie D. Smith(Children's Mercy Hospital), Atul Mehta(University College London), Pilar Giraldo(Université Paris-Saclay), Nan Wang(Weifang Medical University), William J. Rhead(Children's Hospital of Wisconsin), Eric Crombez(University of California, Los Angeles), Gregory M. Pastores(New York University)
Cited by 1
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
|Journal of the American Society of Nephrology|2016|421
Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders
|New England Journal of Medicine|2007|357
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
|Orphanet Journal of Rare Diseases|2015|345